Back to Search
Start Over
Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity
- Source :
- Journal of Clinical Gastroenterology. 49:336-344
- Publication Year :
- 2015
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2015.
-
Abstract
- Background The phase 3 studies of telaprevir (T) in combination with peginterferon α-2a and ribavirin (PR) in treatment-naive genotype 1 chronic hepatitis C virus-infected patients (ADVANCE/ILLUMINATE) were not designed a priori to assess the effect of race and ethnicity on treatment response. However, these factors are important given the lower sustained virologic response (SVR) rates observed in black and Hispanic/Latino patients treated with PR. Goals This retrospective pooled analysis evaluated the effect of race or ethnicity on treatment-naive patient response to telaprevir-based therapy and assessed resistant variant profiles. Materials and methods This analysis comprised patients enrolled in ADVANCE (N=363) and ILLUMINATE (N=540) who received 12 weeks of telaprevir in combination with PR followed by 12 or 36 weeks of PR alone and patients in ADVANCE (N=361) who received 48 weeks of PR alone. Race and ethnicity were self-reported and not mutually exclusive. Results Higher SVR rates were observed with telaprevir-based therapy compared with PR in blacks [n=99 (62%) vs. n=28 (29%), respectively] and in Hispanics/Latinos [n=89 (72%) vs. n=38 (39%)]. The SVR was lower in telaprevir-treated blacks [n=99 (62%)] compared with nonblacks [n=791 (78%)] and in Hispanic/Latinos compared with non-Hispanics/Latinos [n=89 (72%) vs. n=801 (76%)]. Low discontinuation rates due to adverse events, including rash and anemia, were observed across subgroups. Resistance profiles were similar among the subgroups. Conclusions Treatment-naive black and Hispanic/Latino patients with genotype 1 chronic hepatitis C virus infection may benefit from telaprevir-based therapy, an important finding given the lower SVR rates observed in these patients when they are treated with PR alone.
- Subjects :
- Adult
Male
medicine.medical_specialty
Genotype
Hepatitis C virus
Alpha interferon
Hepacivirus
medicine.disease_cause
Antiviral Agents
Gastroenterology
Polyethylene Glycols
Telaprevir
Young Adult
chemistry.chemical_compound
Internal medicine
Ribavirin
medicine
Humans
Aged
Retrospective Studies
business.industry
Interferon-alpha
Hepatitis C
Hepatitis C, Chronic
Middle Aged
Viral Load
medicine.disease
Non-Hispanic whites
Recombinant Proteins
Discontinuation
chemistry
Immunology
Drug Therapy, Combination
Female
business
Oligopeptides
Viral load
medicine.drug
Subjects
Details
- ISSN :
- 01920790
- Volume :
- 49
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Gastroenterology
- Accession number :
- edsair.doi.dedup.....b57efcba94f65cffbf046e933d2a0530